Survodutide Research Guide: Mechanism, Trials and Status

The first major human evidence for survodutide in obesity came from a 46-week, randomised, double-blind, placebo-controlled, dose-finding phase 2 trial in 387 adults with overweight or obesity but without diabetes. Participants received once-weekly survodutide at 0.6 mg, 2.4 mg, 3.6 mg or 4.8 mg, or placebo.^[1]

Mean body-weight change from baseline to week 46 ranged from −6.2% on the lowest dose to −14.9% on the highest dose, against −2.8% with placebo. Adverse events, mostly gastrointestinal and described as mild to moderate, occurred in 75% of participants on survodutide against 42% on placebo.^[1]

SYNCHRONIZE-1, published in the New England Journal of Medicine in 2026, was a 76-week, randomised, double-blind, placebo-controlled phase 3 trial in 725 adults with a body-mass index of 30 or higher, or 27 or higher with an obesity-related complication, who did not have diabetes. Participants were randomly assigned in equal groups to once-weekly survodutide at a dose adjusted up to 3.6 mg, up to 6.0 mg, or placebo, alongside lifestyle counselling.^[3]

Using the trial's primary treatment-regimen estimand, mean body weight fell by 12.2% on the 3.6 mg dose and 13.0% on the 6.0 mg dose, against 5.4% with placebo, and 72.6% and 71.9% of participants respectively lost at least 5% of body weight, against 46.3% with placebo. Gastrointestinal symptoms, typically mild to moderate, occurred in 80.9% and 89.7% of the two survodutide groups against 47.9% with placebo; no deaths were reported.^[3]

A companion phase 3 trial, SYNCHRONIZE-2, enrolled adults with obesity who also have type 2 diabetes; its baseline characteristics were published in 2026, and the trial is recorded as completed on ClinicalTrials.gov, but a full results paper had not appeared in print as of September 2026.^[4][7]

A separate cardiovascular-safety trial, SYNCHRONIZE-CVOT, tested survodutide against placebo in people with overweight or obesity and elevated cardiovascular risk. It is also recorded as completed on ClinicalTrials.gov, though its results had not been published as of September 2026.^[8]

A phase 2 trial published in the New England Journal of Medicine in 2024 tested survodutide against placebo in adults with biopsy-confirmed MASH and liver fibrosis stages F1 to F3, over 48 weeks (a 24-week dose-escalation period followed by 24 weeks of maintenance), at doses of 2.4 mg, 4.8 mg or 6.0 mg.^[2]

Improvement in MASH without worsening of fibrosis occurred in 47%, 62% and 43% of participants on the three survodutide doses, against 14% with placebo. A liver-fat reduction of at least 30% occurred in 63%, 67% and 57% of participants, against 14% with placebo, and fibrosis improved by at least one stage without MASH worsening in 34%, 36% and 34% of participants, against 22% with placebo.^[2]

A phase 3 trial, SYNCHRONIZE-MASLD, published in Nature Medicine in 2026, tested a single 6.0 mg survodutide dose against placebo (2:1 randomisation) in 216 adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD). Using the trial's efficacy estimand, 84.2% of survodutide-treated participants had at least a 30% reduction in MRI-measured liver fat at 48 weeks, against 24.3% with placebo, and mean body weight fell by 12.2% against 1.0% with placebo; both figures were smaller under the trial's more conservative treatment-regimen estimand. Gastrointestinal events were again among the most common adverse events.^[5]

Two further phase 3 trials target MASH with more advanced fibrosis. LIVERAGE is studying survodutide in an estimated 1,800 adults with MASH and moderate or advanced fibrosis; LIVERAGE-Cirrhosis is studying it in an estimated 1,590 adults with compensated MASH cirrhosis. Both trials began enrolling in late 2024 and were still recruiting, with no results reported, as of September 2026.^[9][10]

Across survodutide's published trials, gastrointestinal symptoms — nausea, vomiting and diarrhoea, generally described as mild to moderate — are consistently the most frequently reported adverse events, and they occur more often at higher doses. In the phase 2 obesity trial, gastrointestinal events occurred in 75% of survodutide recipients against 42% with placebo; in the phase 3 SYNCHRONIZE-1 trial, in 80.9% and 89.7% of the two dose groups against 47.9% with placebo.^[1][3]

SYNCHRONIZE-1 reported no deaths among its 725 participants over 76 weeks. Boehringer Ingelheim is separately running a dedicated cardiovascular-safety trial, SYNCHRONIZE-CVOT, reflecting a class-wide question reviews raise about glucagon-receptor co-agonists: because glucagon signalling can raise heart rate, cardiovascular effects are being tracked as a specific research question for this compound class rather than assumed from the weight-loss data alone.^[3][6]

Survodutide and mazdutide are both once-weekly peptides that activate the glucagon and GLP-1 receptors together, but they come from different developers and different trial programmes. Survodutide, sponsored by Boehringer Ingelheim, has been tested mainly in global, multi-country trials; mazdutide has been tested mainly in Chinese trial populations and holds its only regulatory approvals in China, for weight management and type 2 diabetes.^[3]

The two compounds have not been compared head-to-head, so neither published record can be used to rank one above the other; differences in population, dose and duration across each research programme all affect the reported numbers.

No. As of September 2026, survodutide has not been approved by the FDA, the EMA or any other regulatory authority for any use. Its obesity and cardiometabolic trials (SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-CVOT) are recorded as completed, and its MASH-with-fibrosis trials (LIVERAGE, LIVERAGE-Cirrhosis) were still recruiting.^[3][9][10]

Peptyds does not supply survodutide. Peptyds does supply retatrutide, a related but structurally different research peptide — a triple receptor agonist that adds the GIP receptor — for laboratory research use only.